Established Cardiovascular Disease in Special Populations

What Defines Established CVD and Why Populations Matter

Established cardiovascular disease refers to a confirmed history of myocardial infarction, ischemic stroke, peripheral arterial disease, coronary revascularization, or symptomatic coronary artery disease. The 2019 ACC/AHA guideline on primary prevention stratifies these patients into very high-risk secondary prevention categories that call for aggressive lipid, blood pressure, and antiplatelet management [1]. But "aggressive" looks different in a 78-year-old woman with stage 4 CKD than in a 52-year-old man with obesity and no diabetes.

Population-level trial data historically skewed toward middle-aged White men. That gap matters. The 2023 AHA presidential advisory on health equity noted that age-adjusted CVD mortality in Black adults is approximately 30% higher than in White adults [2]. Women present with atypical symptoms, receive fewer catheterizations, and are prescribed guideline-directed medical therapy at lower rates [3]. Older adults are frequently excluded from the very trials whose results guide their care. Each of these realities demands a tailored clinical approach rather than a one-protocol-fits-all model.

Older Adults: Balancing Benefit Against Frailty

Adults aged 75 and older carry the highest absolute risk of MACE. High-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) reduces LDL-C and cardiovascular events in this group, as confirmed by a 2019 meta-analysis of 28 trials (N=186,854) by the Cholesterol Treatment Trialists' Collaboration, which found a 21% relative reduction in major vascular events per 1 mmol/L LDL-C lowering regardless of age [4].

The challenge is not efficacy. It is tolerability. Statin-related muscle symptoms affect 7 to 29% of older patients depending on the definition used [5]. Polypharmacy raises drug-interaction risk. Falls compound the danger of dual antiplatelet therapy.

The American Geriatrics Society recommends individualized deprescribing reviews for patients with limited life expectancy (estimated survival <1 year), prioritizing medications with proven short-term benefit [6]. For patients with reasonable functional status and life expectancy exceeding 3 to 4 years, guideline-directed therapy should not be withheld based on age alone. A practical rule: if the patient walked into the clinic, they are probably well enough to benefit from secondary prevention.

Women: Underdiagnosis, Unique Physiology, Distinct Risk Windows

CVD kills more women than all cancers combined. Yet women remain underrepresented in cardiovascular trials; a 2021 analysis in the Journal of the American Heart Association found that women constituted only 38.2% of participants in major cardiovascular outcome trials between 2010 and 2020 [7].

The pathophysiology itself differs. Women are more likely to have coronary microvascular disease, spontaneous coronary artery dissection (SCAD), and takotsubo cardiomyopathy. Standard angiography may appear "normal" while ischemia persists [3]. Sex-specific risk factors include preeclampsia, gestational diabetes, polycystic ovary syndrome, and premature menopause (before age 40), all of which the 2019 ACC/AHA primary prevention guideline now formally recognizes as risk enhancers [1].

The 2024 AHA scientific statement on sex differences in cardiovascular care states: "Failure to recognize sex-specific presentations of ischemic heart disease contributes to delayed diagnosis and worse outcomes in women" [8]. Clinicians should screen women with pregnancy-related complications for long-term CVD risk starting at the postpartum visit, and threshold for functional stress testing should be lower in women presenting with exertional chest discomfort even when resting ECG and troponins are unremarkable.

Hormone replacement therapy (HRT) remains relevant context. The 2022 Menopause Society position statement clarifies that HRT initiated within 10 years of menopause onset or before age 60 does not increase cardiovascular events in healthy women, though it is not indicated solely for cardiovascular protection [9]. In women with established CVD, HRT initiation is generally not recommended.

Type 2 Diabetes and CVD: Where GLP-1 Receptor Agonists Changed the Standard

Roughly 30% of adults with type 2 diabetes have established CVD [10]. The overlap is so common that the ADA Standards of Care 2024 recommend a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit as first-line therapy after metformin in any patient with type 2 diabetes and atherosclerotic CVD, independent of HbA1c [11].

The landmark LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg daily reduced the composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 13% versus placebo over a median 3.8 years (HR 0.87 to 95% CI 0.78 to 0.97, P=0.01) [12]. Cardiovascular death specifically dropped 22%. The SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 to 1.0 mg weekly reduced MACE by 26% over 2.1 years in a similar population (HR 0.74 to 95% CI 0.58 to 0.95, P=0.02) [13].

Dr. John Buse, principal investigator in multiple GLP-1 cardiovascular outcome trials and professor at UNC School of Medicine, has stated: "The cardiovascular benefits of GLP-1 receptor agonists appear to be mediated by anti-inflammatory and anti-atherosclerotic mechanisms independent of glucose lowering or weight loss" [14].

SGLT2 inhibitors offer complementary benefit. The EMPA-REG OUTCOME trial (N=7,020) found empagliflozin reduced cardiovascular death by 38% (HR 0.62 to 95% CI 0.49 to 0.77, P<0.001) in patients with type 2 diabetes and established CVD [15]. The current approach for patients with both conditions: layer a GLP-1 RA for MACE reduction and an SGLT2 inhibitor for heart failure and renal protection when both are tolerated.

Obesity Without Diabetes: The SELECT Trial's Shift

Before SELECT, no weight management medication had demonstrated MACE reduction. The SELECT trial (N=17,604) randomized adults with BMI 27 or greater, established CVD, and no diabetes to semaglutide 2.4 mg weekly or placebo. At a mean follow-up of 39.8 months, semaglutide reduced the primary MACE composite by 20% (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001) [16].

This result matters precisely because it isolates the cardiovascular effect from glucose-lowering. Participants did not have diabetes. The 2023 AHA/ACC guideline update on obesity management cites SELECT as level 1 evidence supporting semaglutide 2.4 mg for cardiovascular risk reduction in patients with overweight or obesity and established atherosclerotic CVD [17].

Subgroup analyses from SELECT showed consistent MACE benefit across age groups (above and below 65), sexes, baseline BMI categories, and baseline statin use. Weight loss averaged 9.4% with semaglutide versus 0.9% with placebo at 104 weeks, but the cardiovascular benefit appeared within the first 8 to 12 months, before maximum weight loss occurred [16]. This timeline supports the hypothesis that anti-inflammatory effects, including reductions in high-sensitivity C-reactive protein of approximately 37%, contribute to early risk reduction independent of body weight changes.

Chronic Kidney Disease: CVD as the Leading Killer

Patients with CKD stages 3 to 5 are far more likely to die of cardiovascular disease than to progress to dialysis. A 2004 analysis in the New England Journal of Medicine established that a 40-year-old with an eGFR of 45 mL/min/1.73 m² has a cardiovascular mortality rate comparable to a 70-year-old with normal kidney function [18]. The relationship is bidirectional: CVD accelerates kidney decline, and kidney disease amplifies every traditional cardiovascular risk factor.

Statin therapy remains effective. The SHARP trial (N=9,270) showed simvastatin plus ezetimibe reduced major atherosclerotic events by 17% (RR 0.83 to 95% CI 0.74 to 0.94, P=0.0021) in patients with CKD not on dialysis [19]. For patients already on dialysis, the evidence is weaker; the 4D and AURORA trials found no significant MACE reduction with statins in hemodialysis patients [20].

GLP-1 receptor agonists show renal co-benefits. The FLOW trial (N=3,533) demonstrated that semaglutide 1.0 mg weekly reduced the composite kidney outcome (sustained eGFR decline of 50% or greater, kidney failure, or renal death) by 24% (HR 0.76 to 95% CI 0.66 to 0.88, P=0.0003) in patients with type 2 diabetes and CKD [21]. Blood pressure targets in CKD-CVD overlap patients should follow the 2021 KDIGO guideline recommendation of systolic BP <120 mmHg when tolerated, using ACE inhibitors or ARBs as first-line agents [22].

Anticoagulation in CKD requires caution. Direct oral anticoagulants are generally preferred over warfarin for atrial fibrillation in CKD stages 3 to 4, but apixaban dose reduction is required at creatinine clearance 25 to 50 mL/min, and data below 25 mL/min are limited [23].

Racial and Ethnic Disparities in CVD Outcomes

The 2023 AHA statistical update reports that age-adjusted CVD mortality per 100,000 population is 260.8 in Black men versus 211.8 in White men and 175.3 in Black women versus 131.2 in White women [2]. Hispanic and Latino adults face elevated rates of metabolic syndrome, with NHANES data showing a prevalence of 35.4% compared with 32.3% in non-Hispanic White adults [24]. South Asian populations carry a 2 to 4-fold higher risk of coronary artery disease compared with European populations, driven partly by insulin resistance and atherogenic dyslipidemia that manifests at lower BMI thresholds [25].

These disparities are not purely biological. Access to care, insurance coverage, neighborhood food environments, chronic stress exposure, and clinician bias all contribute. The REGARDS study (N=30,239) found that Black participants were 30% less likely to receive a statin prescription after a cardiovascular event compared with White participants, even after adjusting for insurance status and comorbidities [26].

Dr. Clyde Yancy, former AHA president and chief of cardiology at Northwestern, has noted: "Structural determinants of health, including residential segregation and differential access to subspecialty care, drive more of the racial gap in cardiovascular mortality than genetics" [27].

Clinical adjustments for specific populations include: recognizing that African American patients with heart failure and reduced ejection fraction benefit from the addition of hydralazine-isosorbide dinitrate (A-HeFT trial, 43% reduction in mortality, P=0.01) [28]; screening South Asian patients for CAD risk at BMI thresholds 2 to 3 kg/m² lower than general population cutoffs; and ensuring Spanish-language or other primary-language resources for medication adherence counseling.

Heart Failure With Preserved Ejection Fraction (HFpEF) Overlap

Approximately half of all heart failure cases are HFpEF, and the condition disproportionately affects older women and patients with obesity. The EMPEROR-Preserved trial (N=5,988) established empagliflozin as the first drug to reduce heart failure hospitalization in HFpEF (HR 0.71 to 95% CI 0.60 to 0.83, P<0.001), with consistent benefit regardless of diabetes status [29].

For obese patients with HFpEF, the STEP-HFpEF trial (N=529) showed semaglutide 2.4 mg weekly improved the Kansas City Cardiomyopathy Questionnaire score by 7.8 points versus placebo, with concurrent 13.3% body weight reduction at 52 weeks [30]. These patients represent a true intersection of special populations: they are often older, female, obese, and carry multiple comorbidities that make isolated disease management impractical.

The management principle across these intersecting populations is layered rather than sequential: optimize statin intensity, add SGLT2 inhibitors for heart failure and renal protection, consider GLP-1 RAs for MACE and weight reduction, titrate blood pressure to target, and address population-specific factors (frailty screening in elderly patients, sex-specific symptom recognition in women, eGFR-based dose adjustments in CKD, structural barriers in minority communities). Each layer adds proven, incremental benefit.